NOVEL K95-5901-1 SUBSTANCE AND METHOD FOR PRODUCING SAME
|Posted date||Oct 30, 2019|
|International application number||2019JP013132|
|International publication number||WO 2019189331|
|Date of international filing||Mar 27, 2019|
|Date of international publication||Oct 3, 2019|
|Title||NOVEL K95-5901-1 SUBSTANCE AND METHOD FOR PRODUCING SAME|
|Abstract||As a result of searching for an antibiotic substance effective for multidrug-resistant Mycobacterium tuberculosis in a microorganism culture solution, the present inventors discovered a novel substance K95-5901-1 having the following structure, within products of an actinobacterium, Actinoplanes sp. K95-5901. This substance expresses a proliferation-inhibiting activity to multidrug-resistant Mycobacterium tuberculosis at a concentration lower than micromole level, and has a very weak cytotoxicity. Consequently, based on this discovery, the present invention provides a novel substance having a proliferation-inhibition activity on Mycobacterium tuberculosis.|
|Outline of related art and contending technology||
2 Tuberculosis infection is specified to include 3 and 1 is one large infection, HIV/AIDS infections include the following single 2 a large number of deaths in the world the second disease. 1,040 Tuberculosis million patient reported that, by year 170 million people died tuberculosis (2016 years, WHO). HIV infection in the user, the tuberculosis 1 5 occupy the third leading cause of death. With respect to the treatment of tuberculosis, as first, rifampicin, isoniazid, ethambutol, streptomycin, ethambutol is, as the second choice, levofloxacin, kanamycin, antileprosy, , para-aminosalicylic acid, cycloserine been used, used in combination of two or more agents 3.
In recent years, a multi-drug resistance resistant to a therapeutic agent of tuberculosis is, the trend for the spread. Rifampicin resistant to the drug of choice for 60 years may be applied to a case of the upstream one million, 49 million of them are multi-drug resistance is considered. Multidrug resistant tuberculosis further and the existing anti-tuberculosis drug resistant tuberculosis shown no effect on the appearance of an ultra-multi-more than half of the world seen in the countries, these measures are in the urgent international society has been a problem.
However, these therapeutic agents by reducing the number of patients newly industrialized countries in association with, the development of new anti-tuberculosis drugs is reduced, the new anti-tuberculosis agent is 40 years on the market and also not 1. Multidrug-resistant tuberculosis and as one of measures against tuberculosis of the ultra-multi, effective against these, in the conventional structure and mechanism of action of therapeutic agents of the different is demanded the development of new therapeutic agents.
Such as an anti-tuberculosis drug, nitroimidazole-based compound, such as CPZEN-45/caprazamycin, Clp protease and the disturbance material has been studied (Non-Patent Document 1). Clp protease disturbance material which is one type of marine is cyclo marin (cyclomarin) from Streptomyces sp. obtained from actinomycetes in heptapeptides. Is cyclo marin, tuberculosis ClpC1 Clp of the action of the sub-units, and run the function to induce cell death. Streptomyces atratusSCSIO ZH16 iramaishin from deep water is isolated from the cyclo marin and analogous compounds, Clp protease disturbance material in the same manner as thought. C of a plurality of homologs iramaishin iramaishin represented by the following structure is a compound, the compound activity against drug resistant tuberculosis (Mycobacteria tuberculosis H37Rv) have been reported to be as low as 9.6μm (Non-Patent Document 2).
|Scope of claims||
放線菌に属する上記式（I）で表される化合物を生産する能力を有する微生物が、アクチノプラネス・エスピー（Actinoplanes sp．）K95－5901（受託番号NITE BP－02658）である請求項3に記載の製造法。
アクチノプラネス・エスピー（Actinoplanes sp．）K95－5901（受託番号NITE BP－02658）株。
|IPC(International Patent Classification)||
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Contact Information for " NOVEL K95-5901-1 SUBSTANCE AND METHOD FOR PRODUCING SAME "
- The Kitasato Institute Kitasato University Intellectual Property Center
- URL: https://www.kitasato-u.ac.jp/en/index.html
- Address: (In Japanese)〒252-0373 神奈川県相模原市南区北里1丁目15番1
- Fax: 81-42-778-9761